Original Article

You have full text access to this OnlineOpen article

African-American/White differences in breast carcinoma†‡

p53 Alterations and other tumor characteristics

  1. Beth A. Jones Ph.D., M.P.H.1,§,*,
  2. Stanislav V. Kasl Ph.D.1,
  3. Christine L. Howe Ph.D.2,
  4. Mary Lachman M.D.3,
  5. Robert Dubrow M.D., Ph.D.1,
  6. Mary McCrea Curnen M.D., M.P.H.1,
  7. Hosanna Soler-Vila Ph.D.1,
  8. Alicia Beeghly M.P.H.1,
  9. Fenghai Duan M.S.1,
  10. Patricia Owens M.S.4

Article first published online: 9 AUG 2004

DOI: 10.1002/cncr.20500

Issue

Cancer

Cancer

Volume 101, Issue 6, pages 1293–1301, 15 September 2004

Additional Information

How to Cite

Jones, B. A., Kasl, S. V., Howe, C. L., Lachman, M., Dubrow, R., Curnen, M. M., Soler-Vila, H., Beeghly, A., Duan, F. and Owens, P. (2004), African-American/White differences in breast carcinoma. Cancer, 101: 1293–1301. doi: 10.1002/cncr.20500

Author Information

  1. 1

    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut

  2. 2

    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut

  3. 3

    Dianon Systems, Inc., Stratford, Connecticut

  4. 4

    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut

  1. §

    Fax: (203) 785-6980

*Department of Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, P.O. Box 208034, New Haven, CT 06510-2084

  1. †

    See related editorial on pages 1261–3, this issue.

  2. ‡

    Certain data used in the current study were obtained from the Connecticut Tumor Registry located in the Connecticut Department of Public Health. The author(s) assume full responsibility for analyses and interpretation of these data.

Publication History

  1. Issue published online: 1 SEP 2004
  2. Article first published online: 9 AUG 2004
  3. Manuscript Accepted: 15 APR 2004
  4. Manuscript Revised: 9 APR 2004
  5. Manuscript Received: 8 JAN 2004

Funded by

  • Department of Defense Breast Cancer Research Program. Grant Number: DAMD17-96-1-6101
  • National Cancer Institute
  • National Institutes of Health Program Project Grant. Grant Number: 5-P01-CA42101

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (105K)

REFERENCES

  • 1
    Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev. 1994; 3: 127–135.
  • 2
    Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994; 272: 947–954.
  • 3
    Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994; 86: 705–712.
  • 4
    Elmore JG, Moceri VM, Carter D, Larson EB. Breast carcinoma tumor characteristics in black and white women. Cancer. 1998; 83: 2509–2515.
    Direct Link:
  • 5
    Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer. 2000; 88: 114–123.
    Direct Link:
  • 6
    Simon MS, Severson RK. Racial differences in breast cancer survival: the interaction of socioeconomic status and tumor biology. Am J Obstet Gynecol. 1997; 176: S233–S239.
  • 7
    Natarajan N, Nemoto T, Mettlin C, Murphy GP. Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer. 1985; 56: 1704–1709.
    Direct Link:
  • 8
    Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002; 11: 601–607.
  • 9
    Hulka BS, Chambless LE, Wilkinson WE, Deubner DC, McCarty KS Sr., McCarty KS Jr. Hormonal and personal effects on estrogen receptors in breast cancer. Am J Epidemiol. 1984; 119: 692–704.
  • 10
    Stanford JL, Szklo M, Boring CC, et al. A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol. 1987; 125: 184–194.
  • 11
    Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer. 1996; 77: 1465–1471.
    Direct Link:
  • 12
    Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992; 84: 845–855.
  • 13
    Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993; 85: 200–206.
  • 14
    Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993; 53: 4960–4970.
  • 15
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177–182.
  • 16
    Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 1998; 82: 1513–1520.
    Direct Link:
  • 17
    Bieche I, Champeme MH, Matifas F, Hacene K, Callahan R, Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet. 1992; 339: 139–143.
  • 18
    Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994; 54: 1630–1633.
  • 19
    Ocal IT, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that Met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003; 97: 1841–1848.
    Direct Link:
  • 20
    Jones BA, Kasl SV, Curnen MG, Owens PH, Dubrow R. Can mammography screening explain the race difference in stage at diagnosis of breast cancer? Cancer. 1995; 75: 2103–2113.
    Direct Link:
  • 21
    Jones BA, Kasi SV, Curnen MG, Owens PH, Dubrow R. Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol. 1997; 146: 394–404.
  • 22
    Howard J, Hankey BF, Greenberg RS, et al. A collaborative study of differences in the survival rates of black patients and white patients with cancer. Cancer. 1992; 69: 2349–2360.
    Direct Link:
  • 23
    Shambaugh EM, Gloeckler Ries L, Young JL, et al. SEER extent of disease—1988 codes and coding instructions. Bethesda: National Cancer Institute, 1988.
  • 24
    Beahrs O, Henson D, Hutter R, et al. Manual for staging of cancer. American Joint Committee on Cancer. Philadelphia: J.B. Lippincott Company, 1988.
  • 25
    Bloom HJG, Richardson W. Histological grading and prognosis in breast cancer: a study of 1209 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11: 359–377.
  • 26
    SAS Institute, Inc.. SAS version 8. Cary, NC: SAS Institute, Inc., 1999.
  • 27
    Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found. 1983; 64: 3–9.
  • 28
    Najjar MF, Rowland M. Anthropometric reference data and prevalence of overweight, United States, 1976–80. Vital and health statistics, Series 11: Data from the National Health Survey, no. 238) (DHHS publication no. (PHS) 87-1688). Hyattsville, MD: National Center of Health Statistics, 1987.
  • 29
    Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet. 1994; 343: 1195–1197.
  • 30
    Katoh A, Breier S, Stemmler N, Specht S, Blanock K, D'Amico F. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease. Anticancer Res. 1996; 16(3A): 1301–1304.
  • 31
    Gammon MD, Hibshoosh H, Terry MB, et al. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev. 1999; 8: 413–419.
  • 32
    Swede H, Moysich KB, Freudenheim JL, et al. Breast cancer risk factors and HER2 over-expression in tumors. Cancer Detect Prev. 2001; 25: 511–519.
  • 33
    Middleton L, Chen V, Perkins George H, Pinn V, Page D. Histopathology of breast cancer among African-American women. Cancer. 2003; 97 ( 1 Suppl ): 253–257.
    Direct Link:
  • 34
    Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 1997; 47: 28–51.
    Direct Link:
  • 35
    Hunter CP. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer. 2000; 88 ( 5 Suppl ): 1193–1202.
    Direct Link:
  • 36
    Dignam JJ. Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000; 50: 50–64.
    Direct Link:
  • 37
    Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer. 1994; 73: 2147–2156.
    Direct Link:
  • 38
    Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995; 55: 1485–1490.
  • 39
    Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 Mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000: 50–56.
  • 40
    Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996; 88: 1054–1059.
  • 41
    Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996; 2: 811–814.
  • 42
    Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995; 1: 1029–1034.
  • 43
    Weiss SE, Tartter PI, Ahmed S, et al. Ethnic differences in risk and prognostic factors for breast cancer. Cancer. 1995; 76: 268–274.
    Direct Link:
  • 44
    Huang WY, Newman B, Millikan RC, et al. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000; 9: 65–71.
  • 45
    Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer. 2001; 92: 37–45.
    Direct Link:
  • 46
    Duncan O. A socioeconomic index for all occupations. In: ReissAJ, editor. Occupations and social status. New York: Free Press of Glencoe, 1961: 109–38.
  • 47
    Stevens G DF. A revised socioeconomic index of occupational status. Soc Sci Res. 1981; 10: 364–395.
View Full Article (HTML) Get PDF (105K)